The purpose of the study is to explore how GT-002 affects certain brain activities in people with schizophrenia. Participants will receive either GT-002, oxazepam, or a placebo and will undergo tests to measure changes in brain function and mood. These tests include monitoring brain waves using a method called EEG, which records electrical activity in the brain, and other assessments to understand how the treatment impacts thinking and attention.

The study will take place over a short period, and participants will be closely monitored for any side effects or changes in their condition. The goal is to gather information on the safety and effectiveness of GT-002 in improving cognitive function in people with schizophrenia, which could lead to better treatment options in the future.

Participants in the study will be randomly assigned to receive either melatonin, quetiapine, or a placebo. The treatment will be given in the form of film-coated tablets, which are taken orally. The study will last for a period of six months, during which the effects of the treatments on sleep and overall well-being will be monitored. The study aims to provide insights into which treatment might be more effective in managing insomnia in adolescents with psychiatric conditions.

Throughout the study, various aspects of the participants’ sleep and mental health will be assessed. This includes measuring the severity of insomnia using the Insomnia Severity Index, evaluating sleep quality, and assessing psychosocial functioning and subjective well-being. The study will also look at how the treatments affect rest-sleep-activity cycles and other physiological variables. The findings from this study could help improve treatment options for young people dealing with both psychiatric disorders and sleep difficulties.

The purpose of the study is to compare the effectiveness of this intensified treatment with the usual treatment in reducing symptoms of these conditions. Participants will receive either the intensified treatment or the usual treatment for six weeks. The study will monitor changes in symptom severity using a tool called the Positive and Negative Syndrome Scale (PANSS), which helps measure the severity of symptoms in these disorders. The study will also look at other aspects such as anxiety, depression, quality of life, and any side effects experienced during the treatment period.

Participants will be observed over a six-week period, during which they will have regular visits to assess their progress. The study aims to provide insights into whether an intensified treatment approach can offer better outcomes for individuals who have not responded well to their initial treatment. This research could help improve treatment strategies for people living with schizophrenia and related disorders.

Participants in the study will be patients diagnosed with schizophrenia or schizoaffective disorders, which are specific types of psychosis. The study will look at the frequency of certain gene variations, known as polymorphisms, in genes like CYP1A2, MDR1, 5HT2A, 5HT2C, HDAC3, and HDAC4. These genes may influence how patients respond to olanzapine. The study will also assess other factors such as the rate of treatment response, which is measured by a reduction in symptoms, and any side effects experienced during the treatment.

Throughout the study, participants will be monitored for changes in their symptoms and any side effects from the medication. The study will also track how long it takes for participants to show a response to the treatment. This research aims to provide a better understanding of how olanzapine works in treating psychosis and how individual genetic differences can affect treatment outcomes.